<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>An international, Phase II trial was conducted to assess two doses of ofatumumab, a human CD20 monoclonal antibody, combined with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (750 mg/m(2) ), <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> (50 mg/m(2) ), <z:chebi fb="0" ids="8382">prednisone</z:chebi> (100 mg days 3-7) and <z:chebi fb="0" ids="28445">vincristine</z:chebi> (1·4 mg/m(2) ) (O-CHOP), as frontline treatment for follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) </plain></SENT>
<SENT sid="1" pm="."><plain>59 patients with previously untreated FL were randomized to ofatumumab 500 mg (n = 29) or 1000 mg (n = 30) day 1, with CHOP on day 3 every 3 weeks for six cycles </plain></SENT>
<SENT sid="2" pm="."><plain>Median duration of FL was 0·1 years for both dose groups; 34% and 38% of patients had high-risk Follicular <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> International Prognostic Index (FLIPI) scores in the 500- and 1000-mg dose groups, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>Overall response rate was 90% for the 500-mg group and 100% for the 1000-mg group </plain></SENT>
<SENT sid="4" pm="."><plain>62% of patients achieved complete response (CR)/unconfirmed CR (CRu) </plain></SENT>
<SENT sid="5" pm="."><plain>76% of patients with FLIPI score 3-5 attained CR/CRu </plain></SENT>
<SENT sid="6" pm="."><plain>Longer follow-up time is needed for analysis of survival end points </plain></SENT>
<SENT sid="7" pm="."><plain>The most common Common Terminology Criteria grade 3-4 investigator-reported adverse events were <z:e sem="disease" ids="C0023530" disease_type="Disease or Syndrome" abbrv="">leucopenia</z:e> (29%) and <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (22%) </plain></SENT>
<SENT sid="8" pm="."><plain>No <z:hpo ids='HP_0011420'>deaths</z:hpo> have been reported </plain></SENT>
<SENT sid="9" pm="."><plain>O-CHOP was safe and efficacious in patients with previously untreated FL, including high-risk FLIPI groups </plain></SENT>
<SENT sid="10" pm="."><plain>This trial was registered at www.clinicaltrials.gov (NCT00494780) </plain></SENT>
</text></document>